CN110506037A - 芳基环丙基-氨基-异喹啉酰胺化合物 - Google Patents

芳基环丙基-氨基-异喹啉酰胺化合物 Download PDF

Info

Publication number
CN110506037A
CN110506037A CN201880021623.3A CN201880021623A CN110506037A CN 110506037 A CN110506037 A CN 110506037A CN 201880021623 A CN201880021623 A CN 201880021623A CN 110506037 A CN110506037 A CN 110506037A
Authority
CN
China
Prior art keywords
compound
alkyl
ring
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880021623.3A
Other languages
English (en)
Chinese (zh)
Inventor
米契尔·A·德龙
吉尔·M·斯特迪文特
辛西娅·L·利绍罗维克
安德烈·科尔尼洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aerie Pharmaceuticals Inc
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of CN110506037A publication Critical patent/CN110506037A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880021623.3A 2017-03-31 2018-03-30 芳基环丙基-氨基-异喹啉酰胺化合物 Pending CN110506037A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480239P 2017-03-31 2017-03-31
US62/480,239 2017-03-31
US201862643131P 2018-03-14 2018-03-14
US62/643,131 2018-03-14
PCT/US2018/025494 WO2018183911A1 (en) 2017-03-31 2018-03-30 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Publications (1)

Publication Number Publication Date
CN110506037A true CN110506037A (zh) 2019-11-26

Family

ID=63678156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880021623.3A Pending CN110506037A (zh) 2017-03-31 2018-03-30 芳基环丙基-氨基-异喹啉酰胺化合物

Country Status (11)

Country Link
US (3) US10858339B2 (https=)
EP (1) EP3609871A4 (https=)
JP (1) JP2020515583A (https=)
KR (1) KR20190135027A (https=)
CN (1) CN110506037A (https=)
AU (2) AU2018243687C1 (https=)
BR (1) BR112019020078A2 (https=)
CA (1) CA3057872A1 (https=)
MX (1) MX2019011784A (https=)
SG (1) SG11201908179UA (https=)
WO (1) WO2018183911A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113072538A (zh) * 2020-01-06 2021-07-06 广东东阳光药业有限公司 RORγt抑制剂及其在药物中的应用
WO2023274257A1 (zh) * 2021-07-01 2023-01-05 诸葛国琴 一种咪唑类化合物、其中间体及应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20190135027A (ko) * 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
AU2019337703B2 (en) * 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020176579A1 (en) * 2019-02-26 2020-09-03 Aerie Pharmaceuticals, Inc. Thienyl cyclopropyl-amino-isoquinolinyl amide compounds
US12459956B2 (en) 2019-09-13 2025-11-04 Alcon Inc. Heterobicyclic carboxamides and uses thereof
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN115677676B (zh) * 2022-10-19 2024-10-01 黑龙江中医药大学 一种治疗银屑病的药物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157859A1 (en) * 2002-10-21 2004-08-12 Irm Llc, A Delaware Llc Pyrrolidones with anti-HIV activity
CN101115481A (zh) * 2005-01-28 2008-01-30 Irm责任有限公司 苯基取代的吡咯烷酮类化合物
US20080167340A1 (en) * 2007-01-10 2008-07-10 Aerie Pharmaceuticals, Inc. 6-Aminoisoquinoline Compounds
US20090143381A1 (en) * 2007-11-16 2009-06-04 Hadida Ruah Sara S Modulators of atp-binding cassette-transporters
US20090318485A1 (en) * 2006-07-20 2009-12-24 Kalypsys, Inc. Novel inhibitors of rho kinase
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
WO2011085351A2 (en) * 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
JPS5587771A (en) 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
DK8386A (da) 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
DE3766472D1 (de) 1986-10-28 1991-01-10 Smith Kline French Lab Tetrahydroisochinolin-2-yl-derivate von carbonsaeuren als thromboxan a2-antagonisten.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH01139528A (ja) 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
DE1300150T1 (de) 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
EP0389995B1 (en) 1989-03-28 1995-05-31 Nisshin Flour Milling Co., Ltd. Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0630373A1 (en) 1992-03-12 1994-12-28 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
WO1997023223A1 (en) 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
CN1237157A (zh) 1996-11-12 1999-12-01 阿尔康实验室公司 作为眼压降低剂的前列腺素的顺式－△4类似物
WO1998020881A1 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DE69705421T2 (de) 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel
EP0968183A2 (en) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
WO1998050024A1 (en) 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
BR9811779A (pt) 1997-09-09 2000-09-12 Procter & Gamble Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp
DE69824966T2 (de) 1997-09-09 2005-04-07 Duke University Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste
IL134840A0 (en) 1997-09-09 2001-05-20 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6232344B1 (en) 1997-12-22 2001-05-15 Alcon Laboratories, Inc. 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
WO2000003736A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6720175B1 (en) 1998-08-18 2004-04-13 The Johns Hopkins University School Of Medicine Nucleic acid molecule encoding homer 1B protein
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
EP1185509A2 (en) 1999-05-24 2002-03-13 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
CA2389681C (en) 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
ATE305302T1 (de) 1999-12-28 2005-10-15 Eisai Co Ltd Heterozyklische verbindungen mit sulfonamid- gruppen
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001056607A1 (en) 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
US7087632B2 (en) 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
EP1335901B1 (en) 2000-10-17 2010-04-14 Merck Serono SA Pharmaceutically active sulfanilide derivatives
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
ES2316777T3 (es) 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
JP4481011B2 (ja) 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
WO2003097795A2 (en) 2002-05-13 2003-11-27 Norak Biosciences, Inc. Constitutively translocating cell line
ATE546143T1 (de) 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
US7345158B2 (en) 2002-08-30 2008-03-18 Anges Mg, Inc. Actin related cytoskeletal protein “LACS”
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA05013434A (es) 2003-06-12 2006-03-17 Astellas Pharma Inc Derivados de benzamida o sal del mismo.
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
EP1689393A4 (en) 2003-10-06 2008-12-17 Glaxo Group Ltd PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
JP2005227441A (ja) 2004-02-12 2005-08-25 Konica Minolta Medical & Graphic Inc 光熱写真画像形成材料
US7592357B2 (en) 2004-02-20 2009-09-22 Smithkline Beecham Corporation Compounds
US20080096238A1 (en) 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006009889A1 (en) 2004-06-17 2006-01-26 Smithkline Beecham Corporation Novel inhibitors of rho-kinases
DK1607840T3 (da) 2004-06-18 2015-02-16 Tobii Technology Ab Øjenstyring af et computerapparat
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
WO2006041119A1 (ja) 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
GB0425026D0 (en) 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
JP2008523071A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド Ｍａｐキナーゼの尿素インヒビター
US20080207677A1 (en) 2004-12-31 2008-08-28 Gpc Biotech Ag Napthyridine Compounds As Rock Inhibitors
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US20090005321A1 (en) 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
CN101180273A (zh) 2005-05-25 2008-05-14 惠氏公司 合成6-烷基氨基喹啉衍生物的方法
WO2007008942A2 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP1951253A2 (en) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
EP1962853A1 (en) 2005-12-22 2008-09-03 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
MX2008009557A (es) 2006-01-27 2009-01-07 Shanghai Hengrui Pharm Co Ltd Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona.
JP5476559B2 (ja) 2006-02-10 2014-04-23 国立大学法人九州大学 リン酸化酵素の新規基質ポリペプチド
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
WO2007100880A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
JP2007246466A (ja) 2006-03-17 2007-09-27 Osaka Univ 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法
WO2007142323A1 (ja) 2006-06-08 2007-12-13 Ube Industries, Ltd. 側鎖にスピロ環構造を有する新規インダゾール誘導体
EP2044061A2 (en) 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
BRPI0714782A2 (pt) 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8949825B1 (en) 2006-10-17 2015-02-03 Manageiq, Inc. Enforcement of compliance policies in managed virtual systems
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008049919A2 (en) 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2008079945A2 (en) 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
KR20090103903A (ko) 2006-12-27 2009-10-01 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
RU2468011C2 (ru) 2006-12-27 2012-11-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолина и изохинолинона
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
KR20090092303A (ko) 2006-12-27 2009-08-31 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀린 유도체
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
CA2683647A1 (en) 2007-04-10 2008-10-16 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010019910A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AU2010261206B2 (en) 2009-06-19 2015-10-08 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2944319A1 (en) 2010-11-08 2015-11-18 Arava Bio-Tech Ltd. Buffered ophthalmic compositions and use thereof
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
EP2671883A1 (en) 2012-06-05 2013-12-11 Bioprojet New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
JP2014019650A (ja) 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20150175534A1 (en) * 2012-08-01 2015-06-25 Merck Sharp & Dohme Corp. Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I
CN105051005B (zh) * 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9770466B2 (en) 2015-07-02 2017-09-26 Veloce Biopharma, Llc Ophthalmic composition and methods of use
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
BR112019003232A2 (pt) 2016-08-19 2019-06-18 Aerie Pharmaceuticals Inc compostos de beta-amino-isoquinolinil amida, composições que o incluem e métodos de obtenção
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20190135027A (ko) * 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
BR112020020008A2 (pt) 2018-03-30 2021-01-05 Aerie Pharmaceuticals, Inc. Sais mono ácido de 6-aminoisoquinolinas e seus usos
AU2019337703B2 (en) * 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157859A1 (en) * 2002-10-21 2004-08-12 Irm Llc, A Delaware Llc Pyrrolidones with anti-HIV activity
CN101115481A (zh) * 2005-01-28 2008-01-30 Irm责任有限公司 苯基取代的吡咯烷酮类化合物
US20090318485A1 (en) * 2006-07-20 2009-12-24 Kalypsys, Inc. Novel inhibitors of rho kinase
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
US20080167340A1 (en) * 2007-01-10 2008-07-10 Aerie Pharmaceuticals, Inc. 6-Aminoisoquinoline Compounds
US20090143381A1 (en) * 2007-11-16 2009-06-04 Hadida Ruah Sara S Modulators of atp-binding cassette-transporters
WO2011085351A2 (en) * 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王欣然: "异喹啉类和4-氨基吡啶类Rho激酶抑制剂的研究", 《中国优秀硕士论文全文数据库》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113072538A (zh) * 2020-01-06 2021-07-06 广东东阳光药业有限公司 RORγt抑制剂及其在药物中的应用
CN113072538B (zh) * 2020-01-06 2024-04-05 广东东阳光药业股份有限公司 RORγt抑制剂及其在药物中的应用
WO2023274257A1 (zh) * 2021-07-01 2023-01-05 诸葛国琴 一种咪唑类化合物、其中间体及应用

Also Published As

Publication number Publication date
US20210002253A1 (en) 2021-01-07
BR112019020078A2 (pt) 2020-04-28
EP3609871A4 (en) 2021-01-06
AU2018243687A1 (en) 2019-09-26
CA3057872A1 (en) 2018-10-04
WO2018183911A1 (en) 2018-10-04
SG11201908179UA (en) 2019-10-30
AU2018243687C1 (en) 2020-12-24
AU2018243687B2 (en) 2020-07-09
EP3609871A1 (en) 2020-02-19
JP2020515583A (ja) 2020-05-28
US11312700B2 (en) 2022-04-26
US10858339B2 (en) 2020-12-08
US20230130470A1 (en) 2023-04-27
AU2020250183A1 (en) 2020-11-05
US12018012B2 (en) 2024-06-25
US20180327381A1 (en) 2018-11-15
KR20190135027A (ko) 2019-12-05
MX2019011784A (es) 2019-11-18

Similar Documents

Publication Publication Date Title
CN110506037A (zh) 芳基环丙基-氨基-异喹啉酰胺化合物
EP2326623B1 (en) Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
AU2017312712B2 (en) Beta-amino-isoquinolinyl amide compounds
EP2252589B1 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
AU2022304597A1 (en) Azetidinyl pyrimidines and uses thereof
US12459956B2 (en) Heterobicyclic carboxamides and uses thereof
HK40007624A (en) Beta-amino-isoquinolinyl amide compounds
WO2020176579A1 (en) Thienyl cyclopropyl-amino-isoquinolinyl amide compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191126

WD01 Invention patent application deemed withdrawn after publication